Investigation of the effectiveness of lacosamide in generalized seizures.

Comparative study of the clinical effect and side effects of lacosamide and sodium valproate in reducing and controlling seizures in generalized seizures during six months

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220524054982N1

Enrollment

120

Registered

2022-11-06

Start date

2022-11-22

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized tonic-clonic seizures.. Epilepsy and recurrent seizures

Interventions

Intervention 1: In the intervention group, lacosamide is used orally and monotherapy at a dose of 200 mg twice a day (any brand). Patients are followed up for six months and checked for the number of

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Having generalized tonic-clonic seizures Over eighteen years of age Consent to participate in the study Not taking multiple anticonvulsants at the same time

Exclusion criteria

Exclusion criteria: Willingness of patients to withdraw from the study - Having a chronic disease that interferes with the evaluation of the patient Having heart diseases pregnancy

Design outcomes

Primary

Measure	Time frame
Tonic-clonic seizure. Timepoint: On the first day and three months later and six months after starting the drug. Method of measurement: EEG device and patient bedside.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Amir Hejazi

Ghoum University of Medical Sciences

assh.hejazi@gmail.com+98 25 3612 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026